References
1) Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms . ACS ChemNeuroscienc. 2020 Mar 13. doi: 10.1021/acschemneuro.0c00122
2) Liu Z, Xiao X, Wei X, Li J, Yang , Tan H, Zhu J, Zhang Q, Wu J, Liu L.JComposition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV.MedVirol. 2020 Feb 26. doi: 10.1002/jmv.25726. 2.
3) Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2020 Mar 8.
4) Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W, Ahmed N. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV . Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019.
5) Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.Pathogens. 2020 Mar 4;9(3). pi: E186.
6) Walls AC ,Park YJ ,Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.Cell.2020 Mar 6. pii: S0092-8674(20)30262-2.
7) Imai Y, Kuba K, Penninger JM. Angiotensin-convertingenzyme 2 in acute respiratorydistresssyndrome.Cell Mol Life Sci.2007 Aug;64(15):2006-12.
8) Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.Front Med. 2020 Mar 12. doi: 10.1007/s11684-020-0754-0. [Epub ahead of print]
9) Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
10)Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases.CurrOpinPharmacol. 2018 Jun;40:9-17. doi: 10.1016/j.coph.2017.12.002. Epub 2017 Dec 27.
11) Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies.BiomedPharmacother. 2017 Oct;94:317-325. doi: 10.1016/j.biopha.2017.07.091. Epub 2017 Jul 31.
12) Lindgren BR, AnderssonRG.Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A researchreview. MedToxicolAdverseDrugExp.1989 Sep-Oct;4(5):369-80.
13) Kim J, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM.Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome:A Retrospective Case Control Study.Korean J Crit Care Med.2017 May;32(2):154-163. doi: 10.4266/kjccm.2016.00976. Epub 2017 May 31.
14) Haibo Zhang, Josef M. Penninger, Yimin Li, Nanshan Zhong&Arthur S.Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. SlutskyIntensive Care Medicine (2020).
15) MirabitoColafella KM, Bovée DM, Danser AHJ.The renin-angiotensin-aldosterone system and its therapeutic targets. Exp Eye Res. 2019 Sep;186:107680. doi: 10.1016/j.exer.2019.05.020. Epub 2019 May 23.
16) Slabý A, Zák A. CasLekCesk.Renin, prorenin, and the direct renin inhibitor aliskiren. 2010;149(2):55-60. Review. Czech.
17) Aulakh GK, Sodhi RK, Singh M.An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci. 2007 Aug 2;81(8):615-39. Epub 2007 Jun 28. Review.
18) Ding W, Li X, Wu W,He H, Li Y, Gao L, Gan L, Wang M, Ou S, Liu J. Aliskiren inhibits angiotensin II/angiotensin 1-7(Ang II/Ang1-7) signal pathway in rats with diabetic nephropathy .
19) Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; published online Feb 24.
20) Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; published online Feb 28.
21) Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy 2020; published online Feb 19.
22) Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS . J Virology 2020; published online Jan 29.
23) Li XC, Zhang J, Zhuo JL. Lei Fang, George Karakiulakis, Michael RothThevasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020Published OnlineMarch 11, 2020.
24) Andersson RG, Persson K. ACE inhibitors and their influence on inflammation, bronchial reactivity and cough.EurHeart J. 1994 Aug;15 Suppl C:52-6.
25)Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4. doi: 10.1002/ddr.21656.
26) Drug Saf. 1996 Jul;15(1):72-8.ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Overlack A.